



Survival curves HER2-enriched vs other subgroups in TCGA Breast Cancer Data (n=815,c=760) bc8ff81


HER2-enriched (n=58,c=49) vs NA (n=294,c=279)
Log-Rank Test pval: 0.00611




HER2-enriched (n=58,c=49) vs HER2-enriched (n=58,c=49)




HER2-enriched (n=58,c=49) vs Luminal B (n=127,c=117)
Log-Rank Test pval: 0.41468



HER2-enriched (n=58,c=49) vs Basal-like (n=97,c=87)
Log-Rank Test pval: 0.25167



HER2-enriched (n=58,c=49) vs Luminal A (n=231,c=221)
Log-Rank Test pval: 0.00711



HER2-enriched (n=58,c=49) vs Normal-like (n=8,c=7)
Log-Rank Test pval: 0.47937

